Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSNKY Daiichi Sankyo	$24.41 -2.2%	$23.94	$20.92 ▼ $42.48	$46.58B	N/A	270,056 shs	215,071 shs
MKKGY Merck KGaA	$27.84 +1.7%	$27.63	$24.32 ▼ $39.17	$17.99B	0.96	133,331 shs	92,080 shs
REGN Regeneron Pharmaceuticals	$527.78 -3.6%	$613.08	$520.50 ▼ $1,211.20	$57.70B	0.43	768,296 shs	1.50 million shs
ZTS Zoetis	$159.96 -1.1%	$157.27	$139.70 ▼ $200.33	$71.37B	0.94	2.49 million shs	4.24 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSNKY Daiichi Sankyo	-2.20%	-5.79%	+5.22%	-2.90%	-27.91%
MKKGY Merck KGaA	+1.68%	-1.94%	+6.83%	-3.60%	-15.79%
REGN Regeneron Pharmaceuticals	-3.61%	-12.85%	-8.49%	-25.66%	-44.78%
ZTS Zoetis	-1.12%	+1.61%	+3.97%	-6.66%	-3.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MKKGY Merck KGaA	1.9899 of 5 stars	0.0	3.0	2.5	0.0	1.3	0.0	2.5
REGN Regeneron Pharmaceuticals	4.882 of 5 stars	4.4	5.0	1.7	2.3	2.8	1.7	1.9
ZTS Zoetis	4.861 of 5 stars	4.6	3.0	4.2	0.4	4.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSNKY Daiichi Sankyo	0.00	N/A	N/A	N/A
MKKGY Merck KGaA	3.00	Buy	N/A	N/A
REGN Regeneron Pharmaceuticals	2.88	Moderate Buy	$892.60	69.12% Upside
ZTS Zoetis	3.10	Buy	$212.13	32.61% Upside

Current Analyst Ratings Breakdown

Latest MKKGY, ZTS, REGN, and DSNKY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2025	ZTS Zoetis	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$189.00 ➝ $170.00
5/1/2025	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$940.00 ➝ $810.00
4/30/2025	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$975.00 ➝ $940.00
4/30/2025	REGN Regeneron Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$917.00 ➝ $804.00
4/30/2025	REGN Regeneron Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$750.00 ➝ $700.00
4/30/2025	REGN Regeneron Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$1,051.00 ➝ $943.00
4/30/2025	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$865.00 ➝ $800.00
4/30/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$768.00 ➝ $633.00
4/25/2025	REGN Regeneron Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$759.00 ➝ $652.00
4/23/2025	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,004.00 ➝ $975.00
4/22/2025	REGN Regeneron Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSNKY Daiichi Sankyo	$11.09B	4.20	N/A	N/A	$5.62 per share	4.34
MKKGY Merck KGaA	$22.72B	0.79	$10.16 per share	2.74	N/A	∞
REGN Regeneron Pharmaceuticals	$14.09B	4.10	$34.65 per share	15.23	$268.50 per share	1.97
ZTS Zoetis	$9.29B	7.69	$7.19 per share	22.26	$10.65 per share	15.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSNKY Daiichi Sankyo	$1.39B	$1.03	28.38	22.39	1.72	13.62%	14.53%	7.07%	7/29/2025 (Estimated)
MKKGY Merck KGaA	$3.06B	$1.87	17.19	13.58	2.05	12.89%	10.41%	5.88%	5/21/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	13.79	13.88	2.34	31.07%	16.32%	12.76%	N/A
ZTS Zoetis	$2.49B	$5.57	29.24	23.70	2.78	26.86%	53.82%	18.86%	N/A

Latest MKKGY, ZTS, REGN, and DSNKY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	N/A	MKKGY Merck KGaA	$0.50	N/A	N/A	N/A	$5.32 billion	N/A
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion
4/25/2025	Q4 2025	DSNKY Daiichi Sankyo	N/A	$0.30	N/A	$0.30	N/A	$3.40 billion
3/6/2025	Q4 2024	MKKGY Merck KGaA	$0.47	$0.54	+$0.07	$0.54	$5.40 billion	$5.78 billion
2/13/2025	Q4 2024	ZTS Zoetis	$1.37	$1.40	+$0.03	$1.29	$2.30 billion	$2.32 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSNKY Daiichi Sankyo	N/A	N/A	N/A	N/A	N/A
MKKGY Merck KGaA	$0.33	1.19%	N/A	17.65%	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.67%	N/A	8.96%	N/A
ZTS Zoetis	$2.00	1.25%	+18.66%	35.91%	14 Years

Latest MKKGY, ZTS, REGN, and DSNKY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/9/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025
4/23/2025	MKKGY Merck KGaA		$0.3382	1.25%	4/29/2025	4/30/2025	5/7/2025
2/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.53%	2/20/2025	2/20/2025	3/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSNKY Daiichi Sankyo	0.06	2.77	2.11
MKKGY Merck KGaA	0.28	1.33	0.91
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95
ZTS Zoetis	1.09	1.75	1.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSNKY Daiichi Sankyo	N/A
MKKGY Merck KGaA	0.10%
REGN Regeneron Pharmaceuticals	83.31%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
DSNKY Daiichi Sankyo	N/A
MKKGY Merck KGaA	N/A
REGN Regeneron Pharmaceuticals	7.48%
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSNKY Daiichi Sankyo	17,435	1.91 billion	N/A	Not Optionable
MKKGY Merck KGaA	62,908	646.21 million	N/A	Not Optionable
REGN Regeneron Pharmaceuticals	11,900	109.33 million	101.15 million	Optionable
ZTS Zoetis	13,800	446.18 million	447.08 million	Optionable

MKKGY, ZTS, REGN, and DSNKY Headlines

Recent News About These Companies

William Blair Issues Optimistic Estimate for Zoetis Earnings

May 10 at 1:21 AM | americanbankingnews.com

Zoetis' Q1: Market Overreaction Or Justified Drop?

May 9 at 2:55 PM | seekingalpha.com

Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services

May 9 at 2:02 PM | youtube.com

Zoetis Inc. (ZTS): Among Paul Tudor Jones’ Stock Picks with Huge Upside Potential

May 9 at 7:56 AM | insidermonkey.com

Eagle Global Advisors LLC Acquires 6,239 Shares of Zoetis Inc. (NYSE:ZTS)

May 9 at 7:32 AM | marketbeat.com

EP Wealth Advisors LLC Buys 4,498 Shares of Zoetis Inc. (NYSE:ZTS)

May 9 at 7:21 AM | marketbeat.com

Bokf Na Buys 6,024 Shares of Zoetis Inc. (NYSE:ZTS)

May 9 at 6:04 AM | marketbeat.com

Brevan Howard Capital Management LP Decreases Holdings in Zoetis Inc. (NYSE:ZTS)

May 9 at 5:50 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Captrust Financial Advisors

May 9 at 5:41 AM | marketbeat.com

Aptus Capital Advisors LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

May 9 at 4:50 AM | marketbeat.com

Zoetis: Solid Q1 Results And A Weaker Dollar Provide Support (Upgrade)

May 8 at 4:13 PM | seekingalpha.com

Zoetis (NYSE:ZTS) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS

May 8 at 9:16 AM | marketbeat.com

Zoetis (NYSE:ZTS) Releases FY 2025 Earnings Guidance

May 8 at 8:48 AM | marketbeat.com

Zoetis Inc (ZTS) Q1 2025 Earnings Call Highlights: Strong Organic Growth Amid Competitive Pressures

May 8 at 6:31 AM | finance.yahoo.com

Bridgefront Capital LLC Acquires New Holdings in Zoetis Inc. (NYSE:ZTS)

May 8 at 5:58 AM | marketbeat.com

Bamco Inc. NY Cuts Holdings in Zoetis Inc. (NYSE:ZTS)

May 8 at 5:29 AM | marketbeat.com

Zoetis (NYSE:ZTS) Q1 Earnings Increase With Sales At US$2220 Million

May 7 at 3:28 PM | finance.yahoo.com

Cary Street Partners Financial LLC Invests $15.70 Million in Zoetis Inc. (NYSE:ZTS)

May 7 at 6:44 AM | marketbeat.com

Chapman Financial Group LLC Takes $2.21 Million Position in Zoetis Inc. (NYSE:ZTS)

May 7 at 6:16 AM | marketbeat.com

Baird Financial Group Inc. Has $75.22 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

May 7 at 5:58 AM | marketbeat.com

Bank of America Corp DE Sells 2,847,378 Shares of Zoetis Inc. (NYSE:ZTS)

May 7 at 5:40 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MKKGY, ZTS, REGN, and DSNKY Company Descriptions

Daiichi Sankyo OTCMKTS:DSNKY

$24.41 -0.55 (-2.20%)

As of 05/9/2025 04:00 PM Eastern

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Merck KGaA OTCMKTS:MKKGY

$27.84 +0.46 (+1.68%)

As of 05/9/2025 03:59 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Regeneron Pharmaceuticals NASDAQ:REGN

$527.78 -19.89 (-3.63%)

As of 05/9/2025 04:00 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Zoetis NYSE:ZTS

$159.96 -1.73 (-1.07%)

As of 05/9/2025 03:53 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time